2-Benzyl-5-hydroxymethyl-isoindole-1,3-dione | 868622-70-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-Benzyl-5-hydroxymethyl-isoindole-1,3-dione
• 英文别名: 2-Benzyl-5-(hydroxymethyl)isoindole-1,3-dione
• CAS: 868622-70-2
• 化学式: C₁₆H₁₃NO₃
• 分子量: 267.284
• InChiKey: UMBPRFGUXCXAFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Benzyl-5-hydroxymethyl-isoindole-1,3-dione 在 盐酸 、 sodium methylate 、 氯甲酸乙酯 、 溶剂黄146 、 三乙胺 、 lithium bromide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-(2-Benzyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-N-hydroxy-propionamide
  参考文献：
  名称：

  Design and synthesis of phthalimide-type histone deacetylase inhibitors

  摘要：

  Several hydroxamic acid derivatives with a substituted phthalimicle group as a linker and/or cap structure, prepared during structural development studies based on thalidomide, were found to have historic deacetylase (HDAC)-inhibitory activity. Structure-activity relationship studies indicated that nature of the substituent introduced at the phthalimide nitrogen atom, introduction of a hydroxamic acid structure, and distance between the N-hydroxyl group and the cap structure are important for HDAC-inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.048
• 作为产物：
  描述：

  偏苯三酸酐 在 硼烷 作用下， 以 四氢呋喃 为溶剂， 生成 2-Benzyl-5-hydroxymethyl-isoindole-1,3-dione
  参考文献：
  名称：

  Design and synthesis of phthalimide-type histone deacetylase inhibitors

  摘要：

  Several hydroxamic acid derivatives with a substituted phthalimicle group as a linker and/or cap structure, prepared during structural development studies based on thalidomide, were found to have historic deacetylase (HDAC)-inhibitory activity. Structure-activity relationship studies indicated that nature of the substituent introduced at the phthalimide nitrogen atom, introduction of a hydroxamic acid structure, and distance between the N-hydroxyl group and the cap structure are important for HDAC-inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.048

文献信息

• Benzo-fused compounds for use in treating metabolic disorders
  申请人：Brown Sean P.

  公开号：US20080119511A1

  公开（公告）日：2008-05-22

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，可用于治疗受试者的代谢紊乱等疾病。这些化合物的一般式为I，其中变量和A的定义在此提供。本发明还提供了包含这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱（例如2型糖尿病）的方法。
• BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS
  申请人：Brown Sean P.

  公开号：US20100137323A1

  公开（公告）日：2010-06-03

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L 1 , , L 2 ,M, X, L 3 , and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者代谢紊乱的化合物。这些化合物具有一般式I，其中变量Q、L1、L2、M、X、L3和A的定义在本文中提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱的方法，例如II型糖尿病。
• US7687526B2
  申请人：——

  公开号：US7687526B2

  公开（公告）日：2010-03-30
• [EN] BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS<br/>[FR] COMPOSÉS BENZO-FUSIONNÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：AMGEN INC

  公开号：WO2008030618A1

  公开（公告）日：2008-03-13

  [EN] The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L¹, ?, L², M, X, L³, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
  [FR] L'invention concerne des composés utilisés notamment dans le traitement de troubles métaboliques chez un individu. Lesdits composés ont la formule générale (1), où la définition des variables Q, L¹, ?, L², M, X, L³, et de A est spécifiée dans la description. L'invention concerne également des compositions et des procédés d'utilisation des composés dans la préparation de médicaments et dans le traitement de troubles métaboliques, tels que le diabète de type II.